TVARDI THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
TVARDI THERAPEUTICS, INC. (TVRD) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate of 3.80% for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-08.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate · last filed 2026-08-14
- TVARDI THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2026-03-31 was 3.80%.
- TVARDI THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2025-09-30 was 3.80%.
- TVARDI THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2025-06-30 was 4.00%, a 7.83% decline year-over-year.
- TVARDI THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2024-06-30 was 4.34%.
- TVARDI THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2024 was 3.90%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month |
|---|---|---|---|---|
| 2026-03-31 | 3.80% 10-Q · filed 2026-05-08 | |||
| 2025-09-30 | 3.80% 10-Q · filed 2025-11-13 | |||
| 2025-06-30 | 4.00% 10-Q · filed 2026-08-14 | 4.00% 10-Q · filed 2026-08-14 | ||
| 2024-12-31 | 3.90% 10-K · filed 2026-03-31 | |||
| 2024-09-30 | 3.90% 10-Q · filed 2025-11-13 | |||
| 2024-06-30 | 4.34% 10-Q · filed 2024-08-14 | 3.90% 10-Q · filed 2025-08-14 | ||
| 2024-03-31 | 4.12% 10-Q · filed 2025-05-13 | |||
| 2023-09-30 | 4.20% 10-Q · filed 2024-11-14 | |||
| 2019-09-30 | 1.62% 10-Q · filed 2020-11-09 | |||
| 2016-09-30 | 1.19% 10-Q · filed 2016-11-04 | |||
| 2015-09-30 | 1.77% 10-Q · filed 2016-11-04 | |||
| 2014-09-30 | 1.92% 10-Q · filed 2015-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |